Gothenburg, Sweden – 11.05. 2009.

Denator AB announced today that the Department of Pharmacology, at the Penn State College of Medicine, has chosen to integrate the Stabilizor™ T1 system into their proteomic workflows.

Based on the company’s proprietary heat inactivation technology, Stabilizor T1 stabilizes tissue from the crucial moment of sampling, permanently eliminating the activity of degradative enzymes, without the use of additives.

Professor Freeman of the Penn State College of Medicine Department of Pharmacology at the Hershey Center for Applied Research explained: “In our research facility, we are devoted to biomarker development to provide tools for more efficient drug development efforts and as new clinical diagnostics. We are always concerned about post-mortem sample degradation, which has the potential to significantly affect analytical results. Denator’s rapid heat inactivation technology allows us to stabilize tissues instantly and maintain that stability throughout our proteomic and genomic workflows. This will be an important tool for ensuring sample integrity and providing the clearest picture of the molecular basis of biological processes.”

Olof Sköld, CEO at Denator, stated: “We are delighted that such a well-respected center is demonstrating confidence in our system. We believe that Stabilizor T1 represents a true breakthrough in improving the preparation and subsequent analysis of tissue samples. Mr. Sköld added, “We are looking forward to working with Prof. Freeman to realize the full potential of our solution within their research. Working in close collaboration with our customers also gives us valuable feedback to support our development plans for new products that stabilize biological tissues and fluids from the moment of sampling.”

About the Penn State College of Medicine

Enrolling its first students in 1967, the College of Medicine at Penn State Milton S. Hershey Medical Center confers the doctor of medicine and doctor of philosophy degrees. Collectively the College and Medical Center boast a portfolio of approximately $100 million in funded research. Projects range from the development of cancer treatments and advanced diagnostics to groundbreaking neuroscience research into the fundamental causes of disease.

About Denator

Denator intends to become the leading supplier of products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com or contact: